Summary: Using two new immunoradiometric assays for thyrotropin, we measured thyrotropin levels in serum of patients suffering from various clinically and biochemically diagnosed thyroid disorders, and in healthy controls. A thyroliberin Stimulation test was performed in all patients and controls. Thyrotropin levels were measured using a solid phase IRMA in 339 patients and a coated tube sandwich assay in 152 patients. The lower limits of detection of 0.1 mU/1 (solid phase IRMA) and 0.02 mU/1 (coated tube sandwich assay) äs well äs the specificity of these two assays were superior to those of conventional thyrotropin assays. Basal thyrotropin values were clearly different between euthyroid controls and patients non responding to thyroliberin Stimulation. However, the values for these two groups overlapped those for patients showing a subnormal increase upon Stimulation with thyroliberin. The thyroliberin Stimulation test in patients with autonomous adenomas, together with the measurement of thyrotropin using these sensitive assays, provides additional Information in the low ränge below 1.0 mU/1, i. e. below the lower limit of detection of conventional double antibody radioimmunoassays.
Introduction
Recently, new assay methods for thyrotropin based Within the last few years thyrotropin radioimmuno-on the IRMA technique and the use of monoclonal assays using polyclonal antibodies have become suffi-antibodies have been introduced. Major advantages ciently sensitive for the detection of thyrotropin levels of these newly developed methods are higher sensitivi lower than the normal serum ränge. This increase in ity and shorter incubation periods, compared with assay serisitivity, however, involved the use of cum-conventional double antibody radioimmunoassays. bersome pröcedures for tracer purification, and pro-These assays permitted the Separation of healthy conlonged incubation periods (1-4). trols and patients with overt hyperthyroidism using basal thyrotropin levels alone (5) (6) (7) (8) (9) (10) . However, the diagnosis of hyperthyroidism is usually established by measuring increased thyroid hormone levels, and evaluation of thyrotropin secretion is not necessary. For the diagnosis of borderline hyperthyroidism with ambiguous peripheral thyroid hormone levels the performance of a thyroliberin Stimulation test was also necessary. The new thyrotropin assays would be an advantage, if all non-responders to thyroliberin administration could be separated from euthyroid persons using basal thyrotropin levels alone. The Stimulation test with thyroliberin would then no longer be required.
In the present study thyroliberin tests were performed in patients with various clinically and biochemicälly diagnosed thyroid disorders, and in healthy controls. Thyrotropin levels were determined using two new sensitive assays with monoclonal antibodies.
Materials and Methods

New thyrotropin assays using monoclonal antibodies
Solidphase IRMA (Serono Diagnostics): Three different monoclonal antibodies raised against thyrotropin (TSH) were used. Two antibodies labeled with 125 1 are reportedly directed against difierent epitopes both on the a-and ß-subunit of thyrotropin. A third fluorescein isothiocyanate conjugated antibody detects an epitope only present on the ß-subunit of thyrotropin. Standard or serum samples are incubated with these three antibodies for 2 hours. The incubation period is terminated by adding a sheep polyclonal antifluorescein isothiocyanate antibody tagged to a magnetic solid phase. Separation of thyrotropin antibody complex and free antibodies is achieved by exposure to a magnetic field.
Coated tube sandwich assay (RIA gnost, hTSH, Behring): This assay is performed in polystyrene tubes coated with a monoclonal antibody against the ß-subunit of thyrotropin. Standard or serum samples are added together with a second monoclonal antibody reacting with a determinant at the combining site of a-and ß-subunits. This antibody is labeled with 125 I. After incubation the supernatant is decanted, then after washing the tubes are placed into a gamma counter to determine wallbound radioactivity. This assay, now commercially available, was kindly supplied by Behring for clinical evaluation.
Incubation procedures for both assays are detailed in table 1. The coated tube sandwich assay was performed according to the producer's instructions. For easier handiing we prolonged the first incubation period of the solid phase IRMA overnight; to reduce costs, only half of the original ,volumes was used.
Thyroliberin Stimulation test
In all patients a thyroliberin Stimulation test was performed: serum levels of basal thyrotropin and thyrotropin 30 min after injection of 200 g thyroliberin were determined. Thyrotropin levels were measured using a solid phase IRMA from Öctober to November 84 and using a coated tube sandwich assay in December 84. In parallel, a conventional double antibody radioimmunoassay was used (11) . This assay had a lower limit of detection of 1.0 mU/1 and an incubation period of 48 hours.
Other methods
In addition, thyrpxine (T 4 ), triiodothyronine (T 3 ), thyroxine binding globulin (TBG) were measured in all samples in a conventional double antibody fadioimmunoassay (12, 13) .
Patients
Diagnoses of patients included in the present study were based on clinical and biochemical Parameters; in the case of autonomous adenoma diagnosis was achieved by technetium scan. The various thyroid disorders of patients studied are given in table 2. T 4 /TBG ratio and total T 3 were within the normal ränge in alj patients except in those suffering from overt hyperthyroidism. To evaluate the diagnostic validity of basal thyrotropin alone, the following groups were formed according to responsiveness to thyroliberin: first group: no response to thyroliberin (TSH 30 min <0.5 mU/1 meas·-ured with the solid phase IRMA, <0.1 mU/i with the coated tube sandwich assay). This grbup comprises patients with overt hyperthyroidism (elevated thyroid hormone levels) and patients with borderline hyperthyroidism (normal T 4 /TBG ratio and T 3 levels). Patients with borderline hyperthyroidism were suffering from autonomous adenomas, or thyrotoxicosis after beginning drug therapy, or they were under treatment with thyroid hprmones. 
Assay characteristics
The lower limits of detection, based on results for the zero Standard samples, plus 3 SD, were 0.1 mU/1 (solid phase IRMA) and 0.02 mU/1 (coated tube sandwich assay). The intra-and interassay coefficient of Variation for both assays are listed in table 3.
Cross reactivity
In order to evahiate the cross reactivity of the coated tube sandwich assay with chorion gonadotropin, sera from 66 pregnant women without thyroid disorders were investigated. No difference in thyrotropin levels was seen between women in the first trimenon and those in the second or third trimenon. The mean values of thyrotropin were 1.07 ± 1.03 mU/1 (x ± SD, n = 12) within the first trimenon, 1.06 ± 0.7 mU/1 (x ± SD, n = 31) in the second trimenon and 1.19 ± 0.6 mU/1 (x ± SD, n = 23) in the third trimenon.
Validity of the assays Basal thyrotropin levels alone showed a clear discrimination between e thyroid patients and those non responding to thyroliberin. Patients with basal thyrotropin values below the lower limit of detection did not resppnd to thyroliberin (n = 78). In the group of non-responders 32 patients were suffering from overt hyperthyroidism, but 60 patients had normal peripheral thyroid hormone,.leyels (borderline hyperthyroidism). The thyrotropin response to thyroliberin could not be predicted in patients with basal thyrotropin levels ranging from 0.2 to 0.7 mU/1. Thus, patients with thyrotropin-levels of 0.2 and 0.3 m /1 showed no increase (n = 14) or a subnormal response (n = 17) to thyroliberin. Patients with thyrotropin levels from 0.4 up to 0.7 m /1 showed a subnormal inerease (n = 15), but more frequently a normal increase upon Stimulation with thyroliberin (n ^ 59).
Coated tube sandwich assay ( fig. 3) Again, the basal thyrotropin levels alone discriminated between e thyroid patients and non-responders to thyroliberin. Serum thyrotropin levels of 34 of 37 patients non responding to thyroliberin were below the lower limit of detection of 0.02 ni /1; this group comprises all hyperthyroid patients (n = 15). The thyrotropin response to thyroliberin could not be predicted in patients with basal thyrotropin levels ranging from 0.03 to 0.9 mU/1. Two of 7 patients with basal values of 0.03 mU/1 showed no response, and 5 could be stimulated up to 1.0 mU/1. Eleven patients with thyrotropin levels from 0.3 to 0.9 mU/1 showed a subnormal increase, but again more frequently a normal increase was seen (n = 38). The individual thyroliberin test of patients with thyrotropin levels below 0.06 mU/1 are shown in figure 4 .
Euthyroid autonomous adenomas were detected in Tc-scan. Patients with basal thyrotropin values below 0.02 mU/1 and no increase in thyrotropin after thyroliberin showed no paranodular uptake of nuclide (n = 4). In those patients with basal thyrotropin in the r nge of 0.03 and 0.06 mU/1 and a subnormal increase in thyrotropin after thyroliberin administration, the nuclide was found not only in an adenoma, but also in paranodular thyroid tissue. Basal thyrotropin values are plotted versus the 30 min val e aftef thyroliberin administration and measured with the coated tube sandwich β assay. All hyperthyroid patients are below 0.02 mU/1 (n = 15). All other patients, i. e. those with normal pefipheral thyroid hormone levels are below and above 0.02 mU/1 s expected. These patients were suffering from the following thyroid disorders: endemic goitef during thyroid hormone therapy, thyroid carcinoma aftef removal of the thyroid gland during thyroid drug therapy and thyrotoxicosis after beginning drug therapy.
Discussion
In the present study we have demonstrated that a basal thyrotropin value, when determined in highly sensitive assays provides Information on thyroid function almost equivalent to that gained from measurement of basal thyrotropin and thyrotropin 30 min after injection of thyroliberin. This is shown in figure  l where the correlation coefficient between basal and 30 min thyrotropin is 0.79.
Moreover, work, cost and time can be saved in laboratories, out patient clinics and wards by using only basal thyrotropin levels for evaluating thyroid function. Furthermore, the well-known, but usually harmless side effects of thyroliberin injection are avoided.
Both assay Systems used in our study employ monoclonal antibodies against the -subunit of thyrotropin. The inherent advantages of the monoclonal antibody approach are high specificity and sensitivity, compared with conventional double antibody radioimmunoassays. Cross reactivity with human choriongonadotropin and gonadotropins, already excluded theoretically by the design of assay, was not observed when thyrotropin levels were assessed during the course of pregnancy in 66 women.
The use of the IRMA technique allows short incubation periods and provides a high-sensitivity. Even with extremely prolonged incubation periods and sophisticated purification of tracer (1-4), matrix effects prevent the achievment of an equivalent performance by conventional assays. Especially, when measuring low levels of thyrotropin, the new assays displayed a high precision. In contrast, conventional assays show Variation coefficients up to 80% for low thyrotropin values (14) . Both the solid phase IRMA and the coated tube sandwich assay yielded similar values for the intraassay Variation coefficient, which was 5 to 6% with a serum of 0.7 mU/1. The interassay Variation coefficients were also comparable with values of 3.7% and 5.8% with sera of 3.9 and 1.9 mU/1 respectively. Assay handling is more convenient for the coated tube assay äs only one pipetting step is required and Separation is easier.
The validity of both assays is similar in spite of the limit of detection of 0.02 mU/1 for the coated tube Sandwich assay compared with 0.1 mU/1 for the solid phase IRMA. Both assays allow a clearcut discrimination of overt and borderline hyperthyroid patients and euthyroid controls. Normal ranges for both assays were similar with 0.4 to 2.5 mU/1 for the solid phase IRMA and with 0.3 to 2.3 mU/1 for the coated tube sandwich assay.
An additional advantage of a sensitive thyrotropin assay is shown in figure 4 . Basal and 30 min values were measured with the coated tube sandwich assay. The highest 30 min value was 1.0 mU/1. All these thyrotropin values were below the lower limit of detection when measured with a conventional double antibody radioimmunoassay. With the coated tube sandwich assay basal thyrotropin values of all hyperthyroid patients were below the lower limit of detection of 0.02 mU/1. However, all other patients with various thyroid disorders during drug therapy were also either below 0.02 mU/1 or within the ränge of 0.03 to 0.06 mU/1. This is not surprising because one would expect different degrees of thyrotropin suppression depending on the duration of the thyrotoxicosis and drug therapy. In one patient treated with thyroid hormones after removal of the thyroid gland because of carcinoma the basal thyrotropin level was 0.06 niU/1 and showed no response after thyroliberin administration. For this exception no explanation yet is available.
The performance of a thyroliberin Stimulation test in patients with autonomous adenomas may provide additional Information on thyroj^J function. In 4 patients with basal thyrotropin values of 0.02 mU/1, nuclide was only seen in the area of an adenoma in the scan, although peripheral thyroid hormone levels were in the normal ränge. In the other patients with autonomous adenomas and basal thyrotropin values in the ränge of 0.03 to 0.06 mU/1 (n = 7) nuclide was seen not only in the adenoma, but also in the paranodular thyroid tissue. We presume that the difference in thyrotropin secretion is responsible for the paranodular nuclide uptake. Further clinical studies are needed to clarify whether the application of thyroid hormones leads to a total suppression of thyrotropin and consequently to a decrease of paranodular nuclide uptake.
We conclude that both assays provide results enabling a clearcut discrimination of euthyroid controls and of all non-responders to thyroliberin administration (overt and borderline hyperthyroidism) using basal thyrotropin levels alone. There was an overlap of these two groups with patients showing a subnormal increase upon Stimulation with thyroliberin. In patients with autonomous adenomas the performance of a thyroliberin Stimulation test provide additional Information in the low ränge below 1.0 mU/1, i. e. below the lower limit of detection of conventional double antibody radioimmunoassays.
